NCT07460882 The Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertension
| NCT ID | NCT07460882 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 607 participants |
| Start Date | 2026-08-08 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 607 participants in total. It began in 2026-08-08 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this pre-post study is to assess the risk of hyperkalemia in adults with hypertension on medication in Bangladesh. The main questions it aims to answer are: Is the risk of hyperkalemia after the initiation of Low Sodium Salt Substitute (LSSS) in people on antihypertensive medication (especially RASi) large enough to be concerned about its broad use in this population? Does initiation of LSSS correct hypokalemia in people on antihypertensive medication (especially RASi) with low serum potassium levels? Participants will be asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt.
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years with clinically diagnosed hypertension treated with medication \[on a stable dose at least for 2 months\] * Have a phone for contact Exclusion Criteria: * Those with baseline K ≥5.0 or K \<3.0 mmol/L * Advanced kidney disease (eGFR \<45 ml/min/1.73m2). * Those on potassium sparing diuretics (e.g., spironolactone) * Other medical conditions determined by physicians (e.g., heart failure treated with medication; life expectancy less than 12 months) * Dine out for dinner more than 3 times a week
Contact & Investigator
Junichi Ishigami, MD, PhD
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT07460882 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07460882 currently recruiting?
Yes, NCT07460882 is actively recruiting participants. Contact the research team at jishiga1@jhu.edu for enrollment information.
Where is the NCT07460882 trial being conducted?
This trial is being conducted at Dhaka, Bangladesh.
Who is sponsoring the NCT07460882 clinical trial?
NCT07460882 is sponsored by Johns Hopkins University. The principal investigator is Junichi Ishigami, MD, PhD at Johns Hopkins University. The trial plans to enroll 607 participants.